# OnCo record ziv-aflibercept (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ziv-aflibercept/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ziv-aflibercept" ;
  schema:name "Ziv-aflibercept"@en ;
  schema:alternateName "Aflibercept (oncology formulation)"@en, "VEGF Trap"@en, "Zaltrap" ;
  schema:description "Ziv-aflibercept (Zaltrap) is a decoy receptor that soaks up the blood-vessel growth signal VEGF. It is added to the FOLFIRI chemotherapy combination for bowel cancer that has spread and progressed after oxaliplatin."@en ;
  schema:url <https://onco.cc/drugs/ziv-aflibercept/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Aflibercept> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ziv-aflibercept>, <https://www.cancer.gov/about-cancer/treatment/drugs/ziv-aflibercept>, <https://www.ema.europa.eu/en/medicines/human/EPAR/zaltrap>, <https://www.nice.org.uk/guidance/ta307> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Recombinant fusion protein (VEGF ligand trap)" ;
  onco:approval "US 2012: Metastatic colorectal cancer resistant to or progressing after oxaliplatin, with FOLFIRI", "EU 2013: Metastatic colorectal cancer resistant to or progressing after oxaliplatin, with FOLFIRI", "US 2012: Metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen, with FOLFIRI", "EU 2013: Metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen, with FOLFIRI", "England (NICE) 2014: Not recommended" ;
  onco:related <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/folfiri/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/regeneron/> ;
  onco:trials <https://onco.cc/trials/velour/>, <https://onco.cc/trials/nct03172299/>, <https://onco.cc/trials/nct00390234/>, <https://onco.cc/trials/nct01882868/> .